Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerDiagnostic and therapeutic biomarkers in pancreaticobiliary malignancyhENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic reviewSystemic therapies for pancreatic cancer--the role of pharmacogeneticsAlgorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyEquilibrative nucleoside transporters-A review.CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.Nucleotide metabolism, oncogene-induced senescence and cancer.Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer.Therapeutic options for the management of pancreatic cancer.Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapyGemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinomaLooking to the future: biomarkers in the management of pancreatic adenocarcinoma.Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas.The interconnectedness of cancer cell signaling.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancerHigh expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma UndergoiStearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients.A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancerClinicopathological significance of deoxycytidine kinase expression in esophageal squamous cell carcinoma.Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?Molecular endoscopic ultrasound for diagnosis of pancreatic cancer.Role of solute carrier transporters in pancreatic cancer: a review.Current and future biomarkers for pancreatic adenocarcinoma.Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin.
P2860
Q24628746-1C53A443-3934-4914-8A6A-2875331E2176Q26767120-EAB01B6B-EAE3-4899-A5BA-027090D3F3DAQ26862139-CE7BEF14-B575-41D1-B656-3FF0D3A7F671Q27021716-36AA66A1-96FC-4BFA-848A-041BFEFF27AEQ28484288-5E6EF8A8-85B4-4F50-A8DB-0ED06281BD18Q30244329-B9F018F1-FF3F-4742-9325-7953528CABD1Q33630872-4C73E08D-96AB-4C60-82A7-D986862D4499Q33722508-69B347EB-F354-4957-BF91-C9A51BFD14BFQ33969333-606D279F-3DE4-4988-B10E-AC12BF224FEAQ34067856-305F66E6-E640-4AEB-A38D-3CA4CDF328B9Q34093776-F79E6508-063A-4D7F-BD81-ED06BE1FCAFCQ34205171-A6EA5D02-9641-4270-94DE-AEDD075F367BQ34283650-A61CB4E8-C6CB-4C00-ABF8-71A616ED757BQ34507964-57A25105-45A3-4223-95ED-D475FA50BBA0Q34957154-9E72DB04-A31F-4447-A6A2-57D93143C45BQ35066350-2EEE6BA1-7E6F-4A97-BBFE-C78901796D5AQ35086475-700C061F-6D1D-46B9-AA3C-94FA9C3A9B4AQ35196518-40981342-B4D9-45DB-A1A3-5C806CDDD63EQ35297202-8C6E6493-615D-4F99-BB0F-406DE60B81B8Q35444326-1EA17CC2-C540-421E-BD3F-2383E93D8DC2Q35669733-9559EE12-5A39-4321-92E0-54B2B9A69AF4Q35776091-BD837563-9932-4161-9264-DBDD0DA78AA6Q36003248-FDD76FCB-A75B-4946-9167-7A69E70E591BQ36775333-B7B77F3E-95F7-4502-8F4F-E559BB02ECF9Q36796262-7A1641B2-034B-48FE-8484-CCAEF4DD0421Q36822149-06F8309F-DDC1-49F9-BFED-BD84B1B1DD6DQ36887757-FDC202B9-07FE-49FE-8D29-D7721E4BE91FQ36962474-6DE074E7-9361-4FF4-BEFD-4B156B2C0E07Q37268613-EE02632B-CB04-4DF4-AA71-5ED76712042CQ37342736-10BF8AAA-5DD8-4E26-A2C5-663DD047EF19Q37529964-7D9CAD59-3C44-4D99-B88C-BB1D53B88B1FQ37559699-8EED6741-A6A2-4EFA-9B73-C6419EC030EBQ37569554-792A8FEF-B6C8-4767-A5F4-E6F4E765B083Q37870995-C75E3698-370B-40B3-BDB1-DA9C66480FAFQ37994505-3BBC4529-58F8-42D5-9DA3-21A8963EE136Q38125770-578E8620-A75B-46CD-8361-D4F41CE6C93BQ38161338-A32B4E06-7E24-4C99-93EF-DD7B0980E644Q38236028-C42A4223-4D10-48A8-8D8E-5E83BF8C3727Q38670577-ED297E6B-F663-4766-80AD-BA8C4FF4653CQ38707179-64E26C04-62F3-4A61-93E5-BCC547750CA8
P2860
Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Gene expression levels as pred ...... e-based adjuvant chemotherapy.
@ast
Gene expression levels as pred ...... e-based adjuvant chemotherapy.
@en
Gene expression levels as pred ...... e-based adjuvant chemotherapy.
@nl
type
label
Gene expression levels as pred ...... e-based adjuvant chemotherapy.
@ast
Gene expression levels as pred ...... e-based adjuvant chemotherapy.
@en
Gene expression levels as pred ...... e-based adjuvant chemotherapy.
@nl
prefLabel
Gene expression levels as pred ...... e-based adjuvant chemotherapy.
@ast
Gene expression levels as pred ...... e-based adjuvant chemotherapy.
@en
Gene expression levels as pred ...... e-based adjuvant chemotherapy.
@nl
P2093
P2860
P356
P1433
P1476
Gene expression levels as pred ...... ne-based adjuvant chemotherapy
@en
P2093
Hayato Fujita
Kazuhiro Mizumoto
Kohei Nakata
Masao Tanaka
Ryota Souzaki
Soichi Itaba
Tadashi Kayashima
Takao Ohtsuka
Tatsuro Tajiri
P2860
P304
P356
10.1593/NEO.10458
P577
2010-10-01T00:00:00Z